Stock A241820 PCL, INC.
Add to a list
To use this feature you must be a member
Log inSign up

PCL, Inc.

Equities

A241820

KR7241820000

Biotechnology & Medical Research

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
1,201 KRW -0.25% Intraday chart for PCL, Inc. -1.40% -66.50%
Jan. 16 PCL, Inc. announced that it has received KRW 9.99999885 billion in funding from Global Emerging Markets CI
2023 PCL, Inc. announced that it has received KRW 9.99999838 billion in funding from Global Emerging Markets CI

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration

Latest news about PCL, Inc.

PCL, Inc. announced that it has received KRW 9.99999885 billion in funding from Global Emerging Markets CI
PCL, Inc. announced that it has received KRW 9.99999838 billion in funding from Global Emerging Markets CI
PCL, Inc. announced that it expects to receive KRW 9.99999885 billion in funding from Global Emerging Markets CI
PCL, Inc. announced that it expects to receive KRW 9.99999838 billion in funding from Global Emerging Markets CI
South Korean Stocks Close Lower as Uncertainties Around US Debt Ceiling Deal Remain; PCL Loses 13% MT
PCL to Raise 36 Billion Won via Share Issuance MT
PCL, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
PCL, Inc. announced that it has received KRW 2.999990812 billion in funding from Hyeopsim Co ., Ltd. CI
PCL to Raise 3 Billion Won via Share Issuance; Shares Jump 4% MT
PCL, Inc. announced that it expects to receive KRW 2.999990812 billion in funding from Hyeopsim Co ., Ltd. CI
PCL, Inc. terminated the acquisition of 40.76% stake in mCureX Therapeutics, Inc. from OliX Pharmaceuticals, Inc, Samyang Holdings Corporation, AJU Good Growth Support Fund managed by Aju IB Investment Co., Ltd. and Kiwoom New Hero Fund I managed by Kiwoom Investment Co., Ltd. CI
PCL, Inc. announced that it has received KRW 12.060247575 billion in funding CI
OliX Pharmaceuticals, Inc agreed to acquire 6.63% stake in PCL, Inc. for KRW8.04 billion. CI
PCL, Inc. agreed to acquire unknown minority stake in stake in mCureX Therapeutics, Inc. from OliX Pharmaceuticals, Inc, Samyang Holdings Corporation, AJU Good Growth Support Fund managed by Aju IB Investment Co., Ltd. and Kiwoom New Hero Fund I managed by Kiwoom Investment Co., Ltd. for KRW12.2 billion. CI
PCL, Inc.(KOSDAQ:A241820) dropped from S&P Global BMI Index CI
PCL, Inc.(KOSDAQ:A241820) added to S&P Global BMI Index CI
MCureX Therapeutics, Inc. announced that it expects to receive KRW 2 billion in funding from OliX Pharmaceuticals,Inc, PCL, Inc., Samyang Holdings Corporation CI
PCL, Inc. announced that it has received KRW 40.499938368 billion in funding from a group of investors CI
Datametrex AI Limited Secures Authorization by Health Canada for PCL Inc.'s COVID19 Rapid Antigen Test Kit CI
PCL, Inc. announced that it expects to receive KRW 40.499938368 billion in funding from a group of investors CI
Datametrex AI Limited Announces Submission of a Medical Devices Interim Order Request Form to Approve PCL, Inc.’s COV05 COVID19 Rapid Antigen Detection Kits to Health Canada CI
Datametrex AI Limited Secures Rights to Sell and Distribute Pcl, Inc.’s COV05 COVID19 Rapid Antigen Detection Kits CI
PCL, Inc. announced that it has received KRW 9.999993558 billion in funding from Korea Investment Partners Co. Ltd. CI
PCL, Inc. announced that it expects to receive KRW 9.999993558 billion in funding from Korea Investment Partners Co. Ltd. CI
PCL, Inc. has completed an IPO in the amount of KRW 12 billion. CI

Chart PCL, Inc.

Chart PCL, Inc.
More charts

Company Profile

PCL Inc. is a Korea-based company principally engaged in development and manufacture of vitro diagnostic medical device for immunological diagnosis. The Company’s products include blood bank screening products and quick diagnostic products. And the Company also provides platform services.
Sector
Biotechnology & Medical Research
Calendar
2024-05-13 - Q1 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Sector Bio Diagnostics & Testing

1st Jan change Capi.
PCL, INC. Stock PCL, Inc.
-66.50% 47.15M
EXACT SCIENCES CORPORATION Stock Exact Sciences Corporation
-20.45% 10.82B
IOVANCE BIOTHERAPEUTICS, INC. Stock Iovance Biotherapeutics, Inc.
+43.17% 3.25B
GUARDANT HEALTH, INC. Stock Guardant Health, Inc.
-35.86% 2.11B
BGI GENOMICS CO., LTD. Stock BGI Genomics Co., Ltd.
-17.21% 2.08B
VERACYTE, INC. Stock Veracyte, Inc.
-29.81% 1.48B
MARAVAI LIFESCIENCES HOLDINGS, INC. Stock Maravai LifeSciences Holdings, Inc.
+17.56% 1.02B
SEEGENE, INC. Stock Seegene, Inc.
-4.37% 733M
CAREDX, INC Stock CareDx, Inc
-37.00% 391M
ADAPTIVE BIOTECHNOLOGIES CORPORATION Stock Adaptive Biotechnologies Corporation
-46.94% 383M
Bio Diagnostics & Testing
  1. Stock Market
  2. Equities
  3. A241820 Stock
  4. News PCL, Inc.
  5. PCL to Raise 3 Billion Won via Share Issuance; Shares Jump 4%